Eslicarbazepine acetate

Drug Profile

Eslicarbazepine acetate

Alternative Names: Aptiom; BIA 2-093; ESL; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bial
  • Developer BIAL; Eisai Co Ltd; Sunovion Pharmaceuticals
  • Class Acetates; Amides; Analgesics; Antiepileptic drugs; Dibenzazepines; Esters; Small molecules
  • Mechanism of Action Sodium channel antagonists; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase II Migraine
  • Discontinued Bipolar disorders; Fibromyalgia; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 06 Jul 2017 Sunovion initiates enrolment in a phase III trial for Partial epilepsies (In children, In adolescents) in USA (PO) (NCT03108729)
  • 23 Jun 2017 Safety and efficacy data from the phase II BIA-2093-208 clinical trial in Partial seizures released by Eisai
  • 22 May 2017 Registered for Partial epilepsies (Monotherapy, Newly diagnosed) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top